Disclosed is the use of a dopamine receptor D2 inhibitor medicament for treating depression improving cognition and/or treating other syndromes conditions or diseases for which anti-depressant agents are prescribed. The dopamine receptor D2 inhibitor medicament is formulated for administration in an administration cycle the administration cycle comprising: i. administering the D2 receptor inhibitor to elevate amounts of the D2 receptor's high affinity state inducing dopamine receptor supersensit...

1. A method of administering a drug for which the major clearance mechanism in humans is CYP2D6 (CYP-cytochrome P-450) mediated oxidative biotransformation or a pharmaceutically acceptable salt thereof in combination with a CYP2D6 inhibitor or a pharmaceutically acceptable salt thereof to a human in need of the intended pharmaceutical activity of such drug wherein said drug for which the major clearance mechanism in humans is CYP2D6 mediated oxidative biotransformation is selected from the group...

1. A pharmaceutical formulation which comprises in addition to at least one carrier diluent or adjuvant at least one neuroleptic compound in an amount effective to exert a neuroleptic effect in a patient requiring such treatment and melatonin in an amount effective to ameliorate or prevent symptoms of tardive dyskensia developing in the patient. 2. A pharmaceutical formulation according to claim 1 characterized by at least one of the following features: it is adapted for oral rectal parenteral o...